Document:

Exhibit 10.2

 

AMENDMENT NO. 2 TO

CONSULTING AND INTELLECTUAL PROPERTY
(“IP”) AGREEMENT

 

This
Amendment No. 2 to Consulting and Intellectual Property (“IP”) Agreement (this “Amendment”), dated February
15, 2013, is entered into by and between INTERCEPT PHARMACEUTICALS, INC., a
corporation organized and existing under the laws of Delaware, with its registered office at 18 Desbrosses Street, New York, NY
10013, USA (“INTERCEPT”) on the one hand and ROBERTO PELLICCIARI
(“Consultant”), residing at Via U. Rocchi, 60, Perugia, Italy 06123, on the other hand:

 

RECITALS

 

WHEREAS, INTERCEPT and Consultant
have entered into a Consulting and Intellectual Property Agreement, dated August 1, 2011 (the “Original Agreement”),
as amended by Amendment No. 1 to Consulting and Intellectual Property Agreement, dated as of July 30, 2012 (the “First Amendment”
and, the Original Agreement as amended by the First Amendment, the “Agreement”);

 

WHEREAS, the Term (as defined in
the Original Agreement) was extended until January 31, 2013 pursuant to the First Amendment;

 

WHEREAS, the parties have decided
to further extend such Term.

 

NOW, THEREFORE,
in consideration of the foregoing premises, INTERCEPT and Consultant hereby agree as follows:

 

ARTICLE
1: 

 

Article 1.17
of the Agreement shall be deleted and replaced in its entirety as follows:

 

“Research Program”
means the written research plan attached as Exhibit A to this Agreement, setting forth the research activities and services to
be conducted by TES and through the Services provided by the Consultant.

 

ARTICLE
2: 

 

This Amendment shall be of effect starting
on February 1, 2013, and the Term under the Agreement is extended for a six month period starting on February 1, 2013 (hereinafter
the “Extended Term”).

 

During
the Extended Term, Consultant agrees to make himself available to render the Services, as requested
by INTERCEPT at such times and locations as may be mutually agreed and to perform such Services in a professional and workmanlike
manner. INTERCEPT will pay to Consultant thirty-seven thousand five hundred euros (€37,500) for each three-month period
of service during the Extended Term for consulting services and Inventions, Know How, Improvements and Patent Rights, payable as
follows: €37,500 on April 30, 2013 and €37,500 on July 31, 2013.

 

ARTICLE
3: 

 

Exhibit A of the Agreement shall be deleted
and replaced in its entirety with Exhibit A attached to this Amendment.

 

 

 

 

page 1 of 3

Portions of this Exhibit, indicated by the mark “[***],”
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    	 

    
 

 

ARTICLE
4:

 

This Amendment shall be governed by and
construed under the laws of the State of New York, U.S., without giving effect to the conflict of law principles thereof.

 

Any and all provisions of the Agreement
not modified hereinabove shall remain in full force and effect.

 

 

 

[Remainder of Page Intentionally Left
Blank; Signature Page Follows]

 

 

 

 

page 2  of 3

Portions of this Exhibit, indicated by the mark “[***],”
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    	 

    

 

 

In
witness whereof, the Parties have executed this Amendment by their proper officers as of the date first set forth above.

 

 

	 	INTERCEPT PHARMACEUTICALS, INC.
	 	 
	 	/s/ Mark Pruzanski
	 	Name: Mark Pruzanski
	 	Title: President and Chief Executive Officer
	 	 
	 	 
	 	CONSULTANT
	 	 
	 	/s/ Roberto Pellicciari
	 	Name: Roberto Pellicciari

 

 

 

page 3 of 3

[Signature Page – Pellicciari Consulting
Agreement (TGR5)]

Portions of this Exhibit, indicated by the mark “[***],”
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    	 

    

 

Exhibit A

 

[***]

Exhibit A pg. 1 of 3

 

 

 

 

Portions of this Exhibit, indicated by the mark “[***],”
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    	 

    

 

[***]

Exhibit A pg. 2 of 3

 

 

 

 

 

 

Portions of this Exhibit, indicated by the mark “[***],”
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    	 

    

 

[***]

Exhibit A pg. 3 of 3

 

 

 

 

 

 

 

Portions of this Exhibit, indicated by the mark “[***],”
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.Exhibit 10.3

 

AMENDMENT NO. 2 TO

RESEARCH AND DEVELOPMENT AGREEMENT

 

This Amendment No. 2 to Research and Development Agreement,
dated February 15, 2013, is entered into by and between INTERCEPT PHARMACEUTICALS, INC., a corporation organized and existing under
the laws of Delaware, with its registered office at 18 Desbrosses Street, New York, NY 10013, USA (“INTERCEPT”)
on the one hand and TES Pharma Srl, a corporation organized and existing under the laws of Italy, with its registered office at
Via Settevalli 556, 06129, Perugia, Italy (“TES”) on the other hand.

 

RECITALS

 

WHEREAS, INTERCEPT and TES have
entered into a Research and Development Agreement, effective as of August 1, 2011 (the “Original Agreement”), as amended
by Amendment No. 1 to Research and Development Agreement, dated as of July 27, 2012 (the “First Amendment” and, the
Original Agreement as amended by the First Amendment, the “Agreement”);

 

WHEREAS, the Term (as defined in
the Original Agreement) was extended until January 31, 2013 pursuant to the First Amendment;

 

WHEREAS, the parties have decided
to extend such Term.

 

NOW, THEREFORE,
in consideration of the foregoing premises, INTERCEPT and TES hereby agree as follows:

 

ARTICLE
1: 

 

This Amendment shall be of effect starting
on February 1, 2013, and the Term under the Agreement is extended for a six month period starting on February 1, 2013 (hereinafter
the “Extended Term”).

 

Exhibit
A of the Original Agreement and Schedule 1 to the First Amendment shall be deleted and replaced in their entirety with Exhibit
A attached to this Amendment. During the Extended Term, TES shall conduct research activities as set forth in the Research
Program attached as Exhibit A to this Amendment.

 

TES will allocate for the performance of the research activities:
[***] full time equivalent (“FTE”) chemists and [***] FTEs [***] during the Extended Term. INTERCEPT will pay to TES
a maximum amount of €500,000 during the Extended Term of the Agreement, provided such FTEs are allocated and activities performed
in accordance with the Research Program as amended. Payments will be made in equal installments of €250,000 for each three-month
period of service during the Extended Term.

 

TES shall submit to INTERCEPT (i) an intermediate report after
three months from the commencement of the Extended Term and (ii) a final report within 30 days after the end of the Extended Term.

 

ARTICLE
2: 

 

The second paragraph of Article 5.3 of
the Agreement is deleted and replaced in its entirety with the following:

 

TES covenants that until the
later of (a) the end of the Term of the Agreement (as may be further extended) or (b) such date that is the two year anniversary
of the date on which Dr. Pellicciari ceases to be a paid consultant to INTERCEPT, for so long as INTERCEPT has not publicly announced
that it has ceased (directly and indirectly) developing and marketing all Compounds, TES shall not, itself or through one or more
Affiliates or any Third Party, clinically develop, sell, offer for sale, distribute, license, promote or market any chemical entity
and/or active ingredient which is a selective or non-selective TGR5 agonist.

 

 

 

Page 1 of 3

Portions of this Exhibit, indicated by the mark “[***],”
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    	 

    
 

 

ARTICLE
3:

 

This Amendment shall be governed by and
construed under the laws of the State of New York, U.S., without giving effect to the conflict of law principles thereof.

 

Any and all provisions of the Agreement
not modified hereinabove shall remain in full force and effect.

 

[Remainder of Page Intentionally Left
Blank; Signature Page Follows]

 

 

 

 

 

Page 2 of 3

Portions of this Exhibit, indicated by the mark “[***],”
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    	 

    

 

In
witness whereof, the Parties have executed this amendment by their proper officers as of the date first set forth above.

 

 

	 	INTERCEPT PHARMACEUTICALS, INC.	 
	 	 	 
	 	/s/ Mark Pruzanski                   	 
	 	Name: Mark Pruzanski	 
	 	Title: President and Chief Executive Officer	 
	 	 	 
	 	 	 
	 	TES Pharma Srl	 
	 	 	 
	 	/s/ Graeme Robertson              	 
	 	Name: Graeme Robertson	 
	 	Title: Amministratore Delegato	 

 

 

 

Page 3 of 3

 

[Signature Page – TES Agreement
(TGR5)]

Portions of this Exhibit, indicated by the mark “[***],”
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    	 

    

 

Exhibit A

 

[***]

Exhibit A pg. 1 of 3

 

 

 

 

 

Portions of this Exhibit, indicated by the mark “[***],”
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    	 

    

 

[***]

Exhibit A pg. 2 of 3

 

 

 

 

Portions of this Exhibit, indicated by the mark “[***],”
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    	 

    

 

[***]

Exhibit A pg. 3 of 3

 

 

 

 

 

 

Portions of this Exhibit, indicated by the mark “[***],”
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00213-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00213-of-00352.parquet"}]]